Psy63 - Cost by Outcomes Analysis of Novel Triple-Combination Therapies for Relapsed/Refractory Multiple Myeloma in Brazil

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2639
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pcn311 - European Market Access Challenges for Relapsed Refractory Multiple Myeloma Triplet Therapies

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Daratumumab vs. Pomalidomide for the Treatment of Relapsed/Refractory Multiple Myeloma: A Cost‐effectiveness Analysis

American Journal of Hematology
Hematology
2018English

Carfilzomib for Relapsed or Refractory Multiple Myeloma

The Lancet Oncology
Oncology
2018English

Comparative Analysis of Targeted Novel Therapies in Relapsed, Refractory Chronic Lymphocytic Leukaemia

Haematologica
Hematology
2020English

Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma

European Journal of Medical Research
Medicine
2010English

Correction: Management of Relapsed and Refractory Multiple Myeloma: Novel Agents, Antibodies, Immunotherapies and Beyond

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2019English

Treatment Strategies and Outcomes in Patients Treated for Relapsed Refractory Multiple Myeloma Over 3 Years: Premiere Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Low-Dose Lenalidomide and Dexamethasone Combination Treatment in Elderly Patients With Relapsed and Refractory Multiple Myeloma

Hematology
Hematology
2016English

Bendamustine, Pomalidomide, and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy